Are Analysts Bearish ImmunoGen, Inc. (NASDAQ:IMGN) After Last Week?

February 15, 2018 - By Winifred Garcia

 Are Analysts Bearish ImmunoGen, Inc. (NASDAQ:IMGN) After Last Week?
Investors sentiment decreased to 1.16 in 2017 Q3. Its down 0.04, from 1.2 in 2017Q2. It dropped, as 16 investors sold ImmunoGen, Inc. shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported.
Bank & Trust Of Mellon stated it has 548,486 shares or 0% of all its holdings. Clearbridge Invests Ltd Limited Liability Company holds 11.45M shares. Great West Life Assurance Can stated it has 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Citigroup has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Ameriprise Incorporated has invested 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Raymond James Associates holds 457,754 shares. First Manhattan invested in 3,046 shares. Citadel Advsr Llc holds 0% in ImmunoGen, Inc. (NASDAQ:IMGN) or 199,839 shares. Jacobs Levy Equity has invested 0.05% in ImmunoGen, Inc. (NASDAQ:IMGN). Ubs Asset Mgmt Americas reported 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Sg Americas Secs Ltd Liability Corporation has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 10,479 shares. Swiss Retail Bank invested in 138,200 shares or 0% of the stock. Morgan Stanley reported 988,509 shares or 0% of all its holdings. Hall Laurie J Trustee holds 0% or 560 shares. Ftb Advsrs accumulated 0% or 379 shares.

Since September 13, 2017, it had 0 insider purchases, and 2 selling transactions for $262,957 activity. 1,500 shares valued at $10,500 were sold by Berkenblit Anna on Wednesday, September 13.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen had 28 analyst reports since August 3, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of IMGN in report on Tuesday, May 30 with “Hold” rating. Canaccord Genuity maintained it with “Buy” rating and $10.0 target in Wednesday, August 30 report. Jefferies maintained it with “Buy” rating and $11.0 target in Friday, November 3 report. RBC Capital Markets maintained the shares of IMGN in report on Monday, July 27 with “Outperform” rating. Cantor Fitzgerald downgraded ImmunoGen, Inc. (NASDAQ:IMGN) on Monday, August 3 to “Neutral” rating. The rating was maintained by Leerink Swann on Monday, May 2 with “Market Perform”. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Hold” rating by Cowen & Co on Friday, July 28. The company was downgraded on Monday, September 21 by Morgan Stanley. As per Thursday, February 1, the company rating was maintained by Canaccord Genuity. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 3. Below is a list of ImmunoGen, Inc. (NASDAQ:IMGN) latest ratings and price target changes.

08/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Initiate
01/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
03/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $9.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $12.0 Maintain
08/09/2017 Broker: Jefferies Rating: Buy New Target: $9.0 Maintain
30/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.0 Maintain
29/08/2017 Broker: RBC Capital Markets Rating: Buy New Target: $12.0 Maintain

The stock increased 4.78% or $0.4849 during the last trading session, reaching $10.6349. About 2.43 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since February 15, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.41 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: Seekingalpha.com which released: “ImmunoGen Price Run-Up Driven By Potential Clinical Trial Data” on February 06, 2018, also Nasdaq.com with their article: “Earnings Reaction History: ImmunoGen, Inc., 20.0% Follow-Through Indicator, 5 …” published on February 09, 2018, Fool.com published: “Why ImmunoGen Inc. Pulled Back Today” on February 05, 2018. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: Fool.com and their article: “Here’s What’s Lifting ImmunoGen, Inc. Shares Today” published on January 31, 2018 as well as Fool.com‘s news article titled: “What’s Behind ImmunoGen Inc.’s Brief Dip on Tuesday?” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.